Replimune Group Inc. Expects Enrollment Of First Patients In Phase 3 Confirmatory Trial Of RP1 In Advanced Melanoma In 2H 2024
Replimune Group Inc. Expects Enrollment Of First Patients In Phase 3 Confirmatory Trial Of RP1 In Advanced Melanoma In 2H 2024
Replimune Group Inc. 預計將在2024年下半年入組首批患者參加晚期黑色素瘤RP1的3期確認性試驗
Replimune Group Inc. Expects Enrollment Of First Patients In Phase 3 Confirmatory Trial Of RP1 In Advanced Melanoma In 2H 2024
Replimune Group Inc. 預計將在2024年下半年入組首批患者參加晚期黑色素瘤RP1的3期確認性試驗
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。